MARKET

SGBCF

SGBCF

Shanghai Henlius
OTCPK
--
NaN%
Closed 09:30 03/16 EDT
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
Roche’s breast cancer drug Perjeta faces copycats as FDA approves first biosimilar
Seeking Alpha · 11/13/2025 19:03
Henlius Biotech in talks with J&J, Roche on cancer drug: report
Seeking Alpha · 09/16/2025 04:24
About SGBCF
Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.

Webull offers Shanghai Henlius Biotech Inc stock information, including OTCPK: SGBCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGBCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGBCF stock methods without spending real money on the virtual paper trading platform.